Drugs / CTX DP
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01916369 | Apr 2014 → Jan 2018 | peripheral arterial disease | ReNeuron Limited | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02117635 | Jun 2014 → Oct 2016 | cerebral infarction, hemiplegia | ReNeuron Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTX DP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02117635 ↗ |
| Modality | Cell therapy | “human neural stem cell product, CTX” NCT01916369 ↗ |
| Route | Intramuscular | “All trial patients will receive 10 intramuscular injections of CTX DP into the gastrocnemius muscle” NCT01916369 ↗ |